Ischemia-modified albumin: a novel blood marker of endoscopic mucosal healing in inflammatory bowel disease
Intestinal Research
; : 75-81, 2024.
Article
en En
| WPRIM
| ID: wpr-1043115
Biblioteca responsable:
WPRO
ABSTRACT
Background/Aims@#The achievement of endoscopic remission is an important therapeutic goal in the treatment of inflammatory bowel diseases (IBD). We aimed to evaluate the role of fecal calprotectin (FCP) and ischemia-modified albumin (IMA) as biomarkers for evaluating IBD disease activity. @*Methods@#A total of 48 patients with IBD (20 with ulcerative colitis and 28 with Crohn’s disease) were included in this study. FCP and serum C-reactive protein levels, erythrocyte sedimentation rate, and IMA were measured in patients with IBD and compared with endoscopic findings. @*Results@#Elevated FCP and serum IMA levels were significantly associated with endoscopic non-mucosal healing. The correlation between FCP and IMA was not significant. Analysis of the receiver operating characteristic curve showed that both FCP and IMA had diagnostic value in predicting non-mucosal healing. When the Ln(FCP)+IMA/10 value was calculated using both factors, the predictive value for non-mucosal healing increased; however, no significant difference was observed. @*Conclusions@#IMA could be a candidate serum biomarker for predicting endoscopic mucosal healing in IBD.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
En
Revista:
Intestinal Research
Año:
2024
Tipo del documento:
Article